Becker's Healthcare August 27, 2024
The American Society of Health-System Pharmacies is speaking out against Johnson & Johnson’s plan to drop upfront discounts for some 340B drugs.
The drugmaker notified disproportionate share hospitals Aug. 23 of a new rebate system for its blood thinner Xarelto and anti-inflammatory drug Stelara. The change, set to take effect Oct. 15, would require hospitals to buy the drugs at commercial prices and then submit data via Beacon’s claims portal to qualify for a rebate.
ASHP said the rebate framework “violates the basic operation” of the 340B program, which is built around prospective discounts. The group expressed concerns that J&J’s rebate model will serve as a test case for other manufacturers to adopt similar policies if the program goes...
Today's Sponsors
Today's Sponsor